On May 2, 2026, the World Health Organization (WHO) received notification from the United Kingdom's National International Health Regulations (IHR) Focal Point regarding a cluster of severe acute respiratory illness aboard a Dutch-flagged cruise ship 1. The vessel, carrying 147 passengers and crew of 23 nationalities, departed Ushuaia, Argentina, on April 1, 2026 and traversed the South Atlantic, with stops including mainland Antarctica, South Georgia, Tristan da Cunha, and Saint Helena 1. As of May 4, 2026, seven cases, two laboratory-confirmed and five suspected, have been identified, including three deaths 1. This outbreak demands immediate scientific attention. Hantavirus cardiopulmonary syndrome (HCPS) is a zoonotic respiratory disease caused by viruses of the genus Orthohantavirus, family Hantaviridae 1. In the Americas, Orthohantavirus andesense (Andes virus) is responsible for most HCPS cases in South America 1. Human infection is primarily acquired via inhalation of aerosols from rodent urine, feces, or saliva 1, 2. Clinical presentation includes fever, myalgia, gastrointestinal symptoms, and rapid progression to acute respiratory distress syndrome and shock findings consistent with all four confirmed and suspected cases in this outbreak 1. The epidemiology of this cluster is remarkable. Cases 1 and 2 had both traveled through Argentina prior to boarding 1. Case 1, an adult male, developed fever and diarrhea on April 6 and died on April 11 without microbiological confirmation 1. Case 2, a close contact of Case 1, deteriorated in flight to Johannesburg and died on April 26; PCR subsequently confirmed hantavirus 1. Case 3 was confirmed by PCR on May 2 and is currently in intensive care 1. Case 4, with symptom onset on April 28, died on May 2 1. The sequential clustering among close contacts raises concern for limited human-to-human transmission a phenomenon documented previously for Andes virus 3, 4. Although uncommon, human-to-human transmission of Andes virus via close and prolonged contact has been reported, including among household contacts and healthcare workers 1, 4. The close-quarters nature of cruise ship travel shared dining, accommodation, and ventilation systems creates conditions analogous to the community settings in which such transmission has occurred 3. This risk profile is distinct from typical HCPS exposures in rural or occupational settings 1, 2. The case fatality rate (CFR) in this cluster is currently 43% (3/7), consistent with the known CFR of HCPS in the Americas of up to 50% 1, 5. Globally in 2025, 8 countries in the Americas reported 229 cases with a CFR of 25.7% 6. No approved antiviral treatment or vaccine exists for HCPS 1, 7. Ribavirin, despite efficacy in hemorrhagic fever with renal syndrome, has not demonstrated effectiveness against HCPS 1. Management relies entirely on intensive supportive care fluid management, vasopressors, mechanical ventilation, and, in refractory cases, extracorporeal membrane oxygenation 1, 2. Diagnosis of HCPS rests on serologic detection of IgM antibodies or rising IgG titers, alongside reverse transcription polymerase chain reaction (RT-PCR) for viral RNA during the acute phase 1, 8. Early diagnosis remains challenging, as initial symptoms mimic influenza, COVID-19, leptospirosis, and sepsis 8. In this outbreak, a delay in testing Case 1 precluded microbiological confirmation, highlighting the diagnostic gap that persists in travel and maritime medicine settings. This event highlights three urgent priorities. First, ecotourism vessels traversing regions endemic for South American hantaviruses particularly southern Argentina and Chile represent an underrecognized risk vector 1, 9. Pretravel risk counseling and onboard surveillance protocols are currently absent from standard cruise medicine guidelines. Second, the multicountry response involving Cabo Verde, the Netherlands, South Africa, Spain, and the United Kingdom underscores the IHR's critical role in coordinating rapid cross-border containment 10. Third, contact tracing for co-passengers on the flight to Johannesburg taken by Case 2 must be expedited, given potential aerosol exposure during clinical deterioration 11. WHO currently assesses the global risk from this event as low 12. However, the novelty of hantavirus transmission in a maritime ecotourism context, the possibility of person-to-person spread, and the absence of specific therapy collectively demand heightened clinical and public health vigilance. Clinicians worldwide evaluating febrile travelers returning from the South Atlantic region should elicit detailed exposure histories and consider hantavirus in the differential diagnosis. This outbreak must serve as a catalyst for updated guidance on hantavirus risk in ecotourism, maritime infection control standards, and international surveillance integration. The author has nothing to report. The author declares no conflicts of interest. Data sharing is not applicable to this article as no data sets were generated or analyzed during the current study.
Suresh Kumar (Fri,) studied this question.